Another approach for intervention in S1P-related pathophysiology has been put into practice by a mAb (monoclonal antibody) that binds and neutralizes S1P and was shown to be effective in mouse xenograft and allograft tumour models [6,11] as well as in a mouse model of wet AMD, i.e. choroidal neovascularization [12]. The gene discussed is MBTPS1; the disease is wet macular degeneration.